Serum anti-Spike antibody titers before and after heterologous booster with mRNA-1273 SARS-CoV-2 vaccine following two doses of inactivated whole-virus CoronaVac vaccine

Robert Sinto; Dwi Utomo; Suwarti Suwarti; Erni J Nelwan; Henry Surendra; Cindy Natasha; Fransiska Fransiska; Deborah Theresia; Adella F Ranitria; Decy Subekti; Nunung Nuraeni; Winahyu Handayani; Mutia Rahardjani; J. Kevin Baird; Susanna Dunachie; Anuraj H Shankar; Raph L Hamers.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21268360

Documentos relacionados

  1. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
  2. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
  3. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
  4. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
  5. Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses.
  6. Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2-Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study.
  7. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.
  8. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  9. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.
  10. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.